The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety
Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), d...
Saved in:
| Published in: | Expert review of medical devices Vol. 22; no. 6; pp. 533 - 544 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
03.06.2025
|
| Subjects: | |
| ISSN: | 1743-4440, 1745-2422, 1745-2422 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.
This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.
LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients. |
|---|---|
| AbstractList | Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.
This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.
LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients. Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa - carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa - entacapone - carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.INTRODUCTIONDevice-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa - carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa - entacapone - carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.AREAS COVEREDThis article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.EXPERT OPINIONLECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients. Introduction: Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson’s disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa–carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa–entacapone–carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe. Areas covered: This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion. Expert opinion: LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients. |
| Author | Metta, Vinod Odin, Per Popławska-Domaszewicz, Karolina Chaudhuri, K Ray |
| Author_xml | – sequence: 1 givenname: Karolina surname: Popławska-Domaszewicz fullname: Popławska-Domaszewicz, Karolina – sequence: 2 givenname: Vinod surname: Metta fullname: Metta, Vinod – sequence: 3 givenname: Per surname: Odin fullname: Odin, Per – sequence: 4 givenname: K Ray surname: Chaudhuri fullname: Chaudhuri, K Ray |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40331578$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kruO1DAUhiO0iL3AI4BS0mTwLYkDFVpxk1aCYqmtE_uY9eCJg53Marp9BypaHm2fBGdnhoKCypfz_ef_ZZ_z4mQIAxbFc0pWlEjyiraCCyHIihFWr5joOlrzR8VZvq8rJhg7edjzaoFOi_OU1oTwpiXsSXEqCOe0buVZ8fv6BkuDW6exAmfQlG6YIqxxPQ_gc8W7LcZdGWzpcRtMGOH-7icOE2gYc6J80BB7txQWKabJLcJv6Mspt54iwrTJ_NLhC8TvbkhhuL_7lUrjEkLC12XIDluHtwuC1joNelfCYMoEFqfd0-KxBZ_w2WG9KL6-f3d9-bG6-vzh0-Xbq0oLQqdK2k7UptPEWCZ71tletrrtTNuxXgowBpuekgUxIDWwvmsy3BohbNM0tOUXBez7plsc516N0W0g7lQAp8YQJ_AqYo4c9Y3ys0qoMuVz2smFISlLGtMgbRTjHJTAxiqJQqpszmtmmGzrPnu83HuMMfyY82OpjUsavYcBw5wUZ4RSKmUtM_rigM79Bs3fOMe_y8CbPaBjSCmiVdpND2HyBzqvKFHLpKjjpKhlUtRhUrK6_kd9NPi_7g-JachB |
| CitedBy_id | crossref_primary_10_1080_17425247_2025_2539962 |
| Cites_doi | 10.1007/s00702-023-02625-6 10.1001/archneur.61.10.1563 10.1002/ajmg.b.32141 10.1007/s40120-023-00533-1 10.1007/s00415-010-5728-8 10.1007/s10072-008-1054-7 10.1007/s40263-021-00888-9 10.1111/ene.15992 10.1208/s12248-012-9439-1 10.1111/ene.15996 10.1007/s00702-017-1799-3 10.1002/mdc3.70046 10.1212/WNL.0000000000002509 10.1016/S1474-4422(18)30295-3 10.1016/S1474-4422(21)00061-2 10.1007/s40120-024-00635-4 10.1002/mds.26855 10.1007/s10072-020-04407-4 10.1007/s40120-024-00629-2 10.1016/bs.irmvd.2024.05.003 10.1177/17562864221108018 10.1002/mds.22557 10.1038/s41598-020-75052-2 10.3233/JPD-171225 10.1016/j.parkreldis.2023.105357 10.1111/ene.15734 10.1155/2020/9716317 10.1111/ene.12846 10.7861/clinmedicine.16-4-365 10.1002/mds.27338 10.1186/s40035-020-00191-5 10.1212/01.WNL.0000149637.70961.4C 10.1016/B978-0-12-374105-9.00340-3 10.3233/JPD-240003 10.1002/mds.28595 10.1002/mdc3.14018 10.1016/S1474-4422(13)70293-X 10.1097/MJT.0000000000001707 10.1007/s12325-021-01747-1 10.3233/JPD-225105 10.1093/ijnp/pyac021 10.1002/mdc3.14240 10.3233/JPD-202022 10.1002/ana.22155 10.1136/jnnp.74.8.1071 10.1016/j.parkreldis.2013.02.006 10.1007/s00702-013-0981-5 10.1016/j.parkreldis.2016.04.016 10.1007/s40263-020-00769-7 10.1159/000113714 10.1038/s41582-024-01034-x 10.1002/mds.26485 10.1016/j.parkreldis.2013.09.007 10.17925/USN.2024.20.1.6 10.3390/jpm14090939 10.1002/mdc3.13239 10.2147/NDT.S1660 10.1002/mds.27216 10.1002/mds.27862 10.3897/folmed.65.e108196 10.1212/WNL.62.1_suppl_1.S39 10.3390/jpm11040254 10.1002/mds.25585 10.1016/S0140-6736(23)01419-8 10.1007/s00415-002-1204-4 10.3233/JPD-181476 10.1111/ene.15386 10.1002/mds.27372 10.1016/j.parkreldis.2020.09.024 10.1002/mds.27027 10.1002/mds.26123 10.1002/mdc3.12303 10.1097/WCO.0000000000001277 10.1016/j.parkreldis.2017.09.018 10.1111/j.1468-1331.2011.03614.x 10.1002/mdc3.13926 10.1080/14737175.2023.2176222 10.1111/ene.16535 10.1016/j.parkreldis.2014.12.012 |
| ContentType | Journal Article |
| CorporateAuthor | Lunds universitets profilområden Institutionen för kliniska vetenskaper, Lund LU Profile Area: Proactive Ageing MultiPark: Multidisciplinary research focused on Parkinson's disease Lunds universitet Profile areas and other strong research environments Lund University Restorative Parkinson Unit Lund University Profile areas Department of Clinical Sciences, Lund Neurology, Lund Strategiska forskningsområden (SFO) Faculty of Medicine Strategic research areas (SRA) Section IV Medicinska fakulteten Sektion IV LU profilområde: Proaktivt åldrande Profilområden och andra starka forskningsmiljöer Neurologi, Lund |
| CorporateAuthor_xml | – name: Faculty of Medicine – name: Medicinska fakulteten – name: Strategiska forskningsområden (SFO) – name: Restorative Parkinson Unit – name: LU profilområde: Proaktivt åldrande – name: Institutionen för kliniska vetenskaper, Lund – name: Strategic research areas (SRA) – name: Neurology, Lund – name: Lunds universitet – name: Department of Clinical Sciences, Lund – name: Lunds universitets profilområden – name: Lund University Profile areas – name: Sektion IV – name: Profilområden och andra starka forskningsmiljöer – name: Lund University – name: Section IV – name: LU Profile Area: Proactive Ageing – name: Neurologi, Lund – name: Profile areas and other strong research environments – name: MultiPark: Multidisciplinary research focused on Parkinson's disease |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS D95 |
| DOI | 10.1080/17434440.2025.2499153 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Lunds universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1745-2422 |
| EndPage | 544 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_f06d6e16_233a_4e6f_8e48_b84352d2875b 40331578 10_1080_17434440_2025_2499153 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 29G 4.4 53G 5GY AAOUU AAYXX ABEIZ ABJNI ABJXJ ABLKL ABXYU ACGFS ACIWK AECIN AENEX AEOZL AESAV AFRVT AGDLA AGMLL AHMBA AIJEM AIRBT AIYSM AIZAD AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BLEHA CCCUG CITATION CS3 DU5 EBS F5P H13 HZ~ IAO IHR KYCEM LJTGL M4Z MV1 O9- P2P RNANH TASJS TBQAZ TCNNB TDBHL TFL TFW TUROJ 0VX 7X7 88E 8AO 8FE 8FG 8FI 8FJ AAGSP AAHJP AANCX ABJCF ABKMU ABUWG ACFRI ADBBV ADTKB AFKRA ALIPV BENPR BGLVJ BPHCQ BVXVI CBZEQ CCPQU CGR CUY CVF CZ9 D1I DDEWX DGYZD ECM EIF EJD EMOBN FYUFA HCIFZ HMCUK IEA ITC KB. KC. M1P NPM OVD PDBOC PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO TEORI UKHRP 7X8 ACLQP ADTPV AFFHD AOWAS D95 |
| ID | FETCH-LOGICAL-c401t-8f945d9c0df28b29fb87c79d792b84adde6b1045d9da8ca2b969c07d44f666173 |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001484040700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1743-4440 1745-2422 |
| IngestDate | Tue Dec 02 03:10:34 EST 2025 Fri Sep 05 17:15:29 EDT 2025 Mon Jul 21 06:06:21 EDT 2025 Sat Nov 29 07:46:40 EST 2025 Tue Nov 18 22:00:34 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | advanced parkinson’s disease infusion pump Device-aided therapy LECIGON medical device levodopa–carbidopa–entacapone |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c401t-8f945d9c0df28b29fb87c79d792b84adde6b1045d9da8ca2b969c07d44f666173 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 40331578 |
| PQID | 3201118858 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_f06d6e16_233a_4e6f_8e48_b84352d2875b proquest_miscellaneous_3201118858 pubmed_primary_40331578 crossref_citationtrail_10_1080_17434440_2025_2499153 crossref_primary_10_1080_17434440_2025_2499153 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-03 |
| PublicationDateYYYYMMDD | 2025-06-03 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Expert review of medical devices |
| PublicationTitleAlternate | Expert Rev Med Devices |
| PublicationYear | 2025 |
| References | e_1_3_5_29_1 e_1_3_5_27_1 e_1_3_5_25_1 e_1_3_5_23_1 e_1_3_5_44_1 e_1_3_5_67_1 e_1_3_5_46_1 e_1_3_5_69_1 e_1_3_5_88_1 e_1_3_5_48_1 e_1_3_5_82_1 e_1_3_5_3_1 e_1_3_5_61_1 e_1_3_5_80_1 e_1_3_5_40_1 e_1_3_5_63_1 e_1_3_5_86_1 e_1_3_5_42_1 e_1_3_5_65_1 e_1_3_5_84_1 e_1_3_5_9_1 e_1_3_5_21_1 e_1_3_5_5_1 e_1_3_5_7_1 e_1_3_5_18_1 e_1_3_5_39_1 e_1_3_5_16_1 e_1_3_5_37_1 e_1_3_5_14_1 e_1_3_5_35_1 e_1_3_5_12_1 e_1_3_5_33_1 e_1_3_5_56_1 e_1_3_5_77_1 e_1_3_5_58_1 e_1_3_5_79_1 e_1_3_5_50_1 e_1_3_5_71_1 e_1_3_5_52_1 e_1_3_5_73_1 e_1_3_5_54_1 e_1_3_5_75_1 e_1_3_5_10_1 e_1_3_5_31_1 Leyden E (e_1_3_5_59_1) 2023 e_1_3_5_28_1 e_1_3_5_26_1 e_1_3_5_24_1 e_1_3_5_22_1 e_1_3_5_45_1 e_1_3_5_66_1 e_1_3_5_47_1 e_1_3_5_68_1 e_1_3_5_83_1 e_1_3_5_60_1 e_1_3_5_81_1 e_1_3_5_41_1 e_1_3_5_62_1 e_1_3_5_87_1 e_1_3_5_43_1 e_1_3_5_64_1 e_1_3_5_85_1 e_1_3_5_8_1 e_1_3_5_20_1 e_1_3_5_4_1 e_1_3_5_6_1 e_1_3_5_17_1 e_1_3_5_38_1 e_1_3_5_15_1 e_1_3_5_13_1 e_1_3_5_36_1 e_1_3_5_11_1 e_1_3_5_34_1 e_1_3_5_55_1 e_1_3_5_78_1 e_1_3_5_57_1 e_1_3_5_19_1 e_1_3_5_70_1 e_1_3_5_72_1 e_1_3_5_51_1 e_1_3_5_74_1 e_1_3_5_53_1 e_1_3_5_76_1 e_1_3_5_32_1 e_1_3_5_30_1 Berit S (e_1_3_5_49_1) 2010; 2 |
| References_xml | – ident: e_1_3_5_34_1 doi: 10.1007/s00702-023-02625-6 – ident: e_1_3_5_55_1 – ident: e_1_3_5_66_1 doi: 10.1001/archneur.61.10.1563 – ident: e_1_3_5_72_1 doi: 10.1002/ajmg.b.32141 – ident: e_1_3_5_87_1 doi: 10.1007/s40120-023-00533-1 – ident: e_1_3_5_57_1 doi: 10.1007/s00415-010-5728-8 – ident: e_1_3_5_38_1 doi: 10.1007/s10072-008-1054-7 – ident: e_1_3_5_60_1 doi: 10.1007/s40263-021-00888-9 – ident: e_1_3_5_50_1 – ident: e_1_3_5_64_1 doi: 10.1111/ene.15992 – ident: e_1_3_5_56_1 doi: 10.1208/s12248-012-9439-1 – ident: e_1_3_5_63_1 doi: 10.1111/ene.15996 – ident: e_1_3_5_9_1 doi: 10.1007/s00702-017-1799-3 – ident: e_1_3_5_74_1 doi: 10.1002/mdc3.70046 – ident: e_1_3_5_15_1 doi: 10.1212/WNL.0000000000002509 – ident: e_1_3_5_4_1 doi: 10.1016/S1474-4422(18)30295-3 – ident: e_1_3_5_6_1 doi: 10.1016/S1474-4422(21)00061-2 – ident: e_1_3_5_18_1 doi: 10.1007/s40120-024-00635-4 – ident: e_1_3_5_29_1 doi: 10.1002/mds.26855 – ident: e_1_3_5_69_1 doi: 10.1007/s10072-020-04407-4 – ident: e_1_3_5_61_1 doi: 10.1007/s40120-024-00629-2 – ident: e_1_3_5_20_1 doi: 10.1016/bs.irmvd.2024.05.003 – ident: e_1_3_5_35_1 doi: 10.1177/17562864221108018 – ident: e_1_3_5_5_1 doi: 10.1002/mds.22557 – ident: e_1_3_5_75_1 doi: 10.1038/s41598-020-75052-2 – ident: e_1_3_5_46_1 doi: 10.3233/JPD-171225 – ident: e_1_3_5_68_1 doi: 10.1016/j.parkreldis.2023.105357 – ident: e_1_3_5_11_1 doi: 10.1111/ene.15734 – ident: e_1_3_5_85_1 – ident: e_1_3_5_79_1 doi: 10.1155/2020/9716317 – ident: e_1_3_5_80_1 doi: 10.1111/ene.12846 – ident: e_1_3_5_8_1 doi: 10.7861/clinmedicine.16-4-365 – ident: e_1_3_5_43_1 doi: 10.1002/mds.27338 – ident: e_1_3_5_23_1 doi: 10.1186/s40035-020-00191-5 – ident: e_1_3_5_36_1 doi: 10.1212/01.WNL.0000149637.70961.4C – ident: e_1_3_5_58_1 doi: 10.1016/B978-0-12-374105-9.00340-3 – ident: e_1_3_5_22_1 doi: 10.3233/JPD-240003 – ident: e_1_3_5_32_1 doi: 10.1002/mds.28595 – ident: e_1_3_5_86_1 doi: 10.1002/mdc3.14018 – ident: e_1_3_5_28_1 doi: 10.1016/S1474-4422(13)70293-X – ident: e_1_3_5_53_1 doi: 10.1097/MJT.0000000000001707 – ident: e_1_3_5_31_1 doi: 10.1007/s12325-021-01747-1 – ident: e_1_3_5_45_1 doi: 10.3233/JPD-225105 – ident: e_1_3_5_62_1 doi: 10.1093/ijnp/pyac021 – ident: e_1_3_5_81_1 doi: 10.1002/mdc3.14240 – ident: e_1_3_5_48_1 doi: 10.3233/JPD-202022 – ident: e_1_3_5_73_1 doi: 10.1002/ana.22155 – ident: e_1_3_5_65_1 doi: 10.1136/jnnp.74.8.1071 – ident: e_1_3_5_78_1 doi: 10.1016/j.parkreldis.2013.02.006 – ident: e_1_3_5_13_1 doi: 10.1007/s00702-013-0981-5 – ident: e_1_3_5_70_1 doi: 10.1016/j.parkreldis.2016.04.016 – ident: e_1_3_5_17_1 doi: 10.1007/s40263-020-00769-7 – ident: e_1_3_5_37_1 doi: 10.1159/000113714 – ident: e_1_3_5_7_1 doi: 10.1038/s41582-024-01034-x – ident: e_1_3_5_44_1 doi: 10.1002/mds.26485 – ident: e_1_3_5_76_1 doi: 10.1016/j.parkreldis.2013.09.007 – ident: e_1_3_5_84_1 doi: 10.17925/USN.2024.20.1.6 – ident: e_1_3_5_71_1 doi: 10.3390/jpm14090939 – ident: e_1_3_5_42_1 doi: 10.1002/mdc3.13239 – ident: e_1_3_5_14_1 doi: 10.2147/NDT.S1660 – ident: e_1_3_5_16_1 doi: 10.1002/mds.27216 – ident: e_1_3_5_21_1 doi: 10.1002/mds.27862 – ident: e_1_3_5_54_1 doi: 10.3897/folmed.65.e108196 – ident: e_1_3_5_67_1 doi: 10.1212/WNL.62.1_suppl_1.S39 – ident: e_1_3_5_30_1 doi: 10.3390/jpm11040254 – ident: e_1_3_5_77_1 doi: 10.1002/mds.25585 – ident: e_1_3_5_3_1 doi: 10.1016/S0140-6736(23)01419-8 – volume: 2 start-page: 1 year: 2010 ident: e_1_3_5_49_1 article-title: Patient-perceived retrospective outcome of duodenal levodopa infusion in advanced Parkinson´s disease publication-title: Eur Neurological J – ident: e_1_3_5_10_1 doi: 10.1007/s00415-002-1204-4 – ident: e_1_3_5_12_1 doi: 10.3233/JPD-181476 – ident: e_1_3_5_26_1 – ident: e_1_3_5_51_1 – ident: e_1_3_5_24_1 doi: 10.1111/ene.15386 – volume-title: Carbidopa year: 2023 ident: e_1_3_5_59_1 – ident: e_1_3_5_25_1 doi: 10.1002/mds.27372 – ident: e_1_3_5_88_1 doi: 10.1016/j.parkreldis.2020.09.024 – ident: e_1_3_5_83_1 doi: 10.1002/mds.27027 – ident: e_1_3_5_39_1 doi: 10.1002/mds.26123 – ident: e_1_3_5_19_1 doi: 10.1002/mdc3.12303 – ident: e_1_3_5_27_1 doi: 10.1097/WCO.0000000000001277 – ident: e_1_3_5_40_1 doi: 10.1016/j.parkreldis.2017.09.018 – ident: e_1_3_5_47_1 doi: 10.1111/j.1468-1331.2011.03614.x – ident: e_1_3_5_52_1 doi: 10.1002/mdc3.13926 – ident: e_1_3_5_33_1 doi: 10.1080/14737175.2023.2176222 – ident: e_1_3_5_82_1 doi: 10.1111/ene.16535 – ident: e_1_3_5_41_1 doi: 10.1016/j.parkreldis.2014.12.012 |
| SSID | ssj0036702 |
| Score | 2.4146183 |
| SecondaryResourceType | review_article |
| Snippet | Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can... Introduction: Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson’s disease (PD)... |
| SourceID | swepub proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 533 |
| SubjectTerms | Antiparkinson Agents - administration & dosage Antiparkinson Agents - therapeutic use Carbidopa - administration & dosage Carbidopa - adverse effects Carbidopa - therapeutic use Catechols - administration & dosage Catechols - adverse effects Catechols - therapeutic use Clinical Medicine Drug Combinations Drug Delivery Systems - instrumentation Gels Humans Jejunum Klinisk medicin Levodopa - administration & dosage Levodopa - adverse effects Levodopa - therapeutic use Medical and Health Sciences Medicin och hälsovetenskap Neurologi Neurology Nitriles - administration & dosage Nitriles - adverse effects Nitriles - therapeutic use Parkinson Disease - drug therapy Treatment Outcome |
| Title | The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40331578 https://www.proquest.com/docview/3201118858 |
| Volume | 22 |
| WOSCitedRecordID | wos001484040700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1745-2422 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036702 issn: 1743-4440 databaseCode: TFW dateStart: 20040901 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6Cwc4IN6UxypI7AmlJM7LPqLCCgm0qlBZKi6WYzu0paRVX7va0_IbOPH39ifwC5iJkzTLrgRIbA9Rm8ZTN_NlPGPPfCbkWcCVhHGGu9r41A0TFrhMG-l6GmIBMIbUZhMevEv299lgwHut1s-qFmY9SfKcHR3x2aWqGs6BsrF09h_UXQuFE_AelA5HUDsc_1rx2qABcJH-EbmVlnM5NuMVOp7aTDATo1hXn5g1BKUzWSU8BJhHruRsmpv6lJLzdIQXFcQSYA9QyGczKRzWTZY6ZtJJnHbH3JKyLV-cWf4Z10l_Zr5slMx8rZaKij7XLn5vOtvtRruMysPFF-m-wjymY3M4UsdlDVux21CNF7O0bvDBKJ_qeuZYW4aE3iYFuTuUKz1c2fr6t53n78skonLig0ZFglbQsNXIrhqGlu2pMuaUNkDbtMyR5ds4N2LYFEuUhaI6-EMdCEm5bzmMLyDjtnGRKMmYhmKyEgsjZo1ZVpF5sY6NHwsaBFKEJs4EMyETKQPvlGqIUqN0i1yhScQxDbG_97HyHpBPj9oiXvvnqqoz5r24sJNn_alzQdJvDLiF19S_SW6U4Y7z0sL0FmmZ_Da53iDBvEO-AWCdJmCdJmCdCrDONHMqwJ6efN9AFT7UIHU2IHUApA6A1KlBihJqkJ6e_Fg4JTzvkg97r_vdN265MYirQs9fuizjYaS58nRGWUp5lrJEJVwnnMIdxhE7Tn0PL9GSKUlTHsPFCZifDKJ1Pwnuke0cOviAOBDtc55AEKKCYvN1HqsIXoFUnqHgnbdJWN1eoUrWfNy8ZSL8kly30opArYhSK23SqZvNLG3Mnxo8rXQnwMDjqp3MzXS1EAG66D5j2Jf7Vqm1yNALAh_G3Db5ZLVcf_MfgfrwMoU_Itc2z_Zjsr2cr8wTclWtl6PFfIdsJQO2UzwgvwC88AWW |
| linkProvider | Taylor & Francis |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+device-aided+intrajejunal+delivery+of+levodopa%E2%80%93entacapone%E2%80%93carbidopa+intestinal+gel+the+treatment+of+Parkinson%E2%80%99s+disease&rft.jtitle=Expert+review+of+medical+devices&rft.au=Pop%C5%82awska-Domaszewicz%2C+Karolina&rft.au=Metta%2C+Vinod&rft.au=Odin%2C+Per&rft.au=Chaudhuri%2C+K.+Ray&rft.date=2025-06-03&rft.issn=1743-4440&rft.volume=22&rft.issue=6&rft.spage=533&rft_id=info:doi/10.1080%2F17434440.2025.2499153&rft.externalDocID=oai_portal_research_lu_se_publications_f06d6e16_233a_4e6f_8e48_b84352d2875b |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-4440&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-4440&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-4440&client=summon |